Q2 EPS Estimates for AngioDynamics Reduced by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO) – Stock analysts at Zacks Research lowered their Q2 2025 earnings estimates for AngioDynamics in a research report issued on Wednesday, October 23rd. Zacks Research analyst D. Dey now forecasts that the medical instruments supplier will post earnings of ($0.12) per share for the quarter, down from their prior forecast of ($0.10). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.41) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS and FY2027 earnings at ($0.16) EPS.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The firm had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. During the same quarter last year, the company posted ($0.12) earnings per share. AngioDynamics’s revenue was down 14.2% on a year-over-year basis.

Other equities research analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research report on Friday, October 4th. Canaccord Genuity Group lowered their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th.

AngioDynamics Trading Down 0.7 %

Shares of AngioDynamics stock opened at $7.09 on Friday. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $8.25. The stock has a market capitalization of $283.99 million, a price-to-earnings ratio of -1.46 and a beta of 0.65. The business’s 50 day simple moving average is $7.16 and its 200-day simple moving average is $6.68.

Insiders Place Their Bets

In other AngioDynamics news, CEO James C. Clemmer purchased 20,000 shares of the stock in a transaction dated Monday, October 7th. The shares were bought at an average cost of $6.03 per share, with a total value of $120,600.00. Following the completion of the acquisition, the chief executive officer now owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders acquired 22,568 shares of company stock worth $135,847. 5.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ANGO. Wealth Enhancement Advisory Services LLC acquired a new stake in AngioDynamics in the third quarter worth approximately $86,000. Ballentine Partners LLC bought a new stake in shares of AngioDynamics in the 3rd quarter worth $141,000. Assenagon Asset Management S.A. lifted its holdings in shares of AngioDynamics by 7.2% in the third quarter. Assenagon Asset Management S.A. now owns 425,108 shares of the medical instruments supplier’s stock valued at $3,307,000 after buying an additional 28,499 shares during the period. CWM LLC boosted its stake in AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 8,832 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in AngioDynamics during the third quarter worth about $103,000. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.